SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that it has completed a series of strategic financial transactions, further strengthening its balance sheet and extending ...

Omeros Corporation (NASDAQ:OMER) is one of the hot stocks to buy with huge upside potential. On October 15, H.C. Wainwright raised the firm’s price target on Omeros to $20 from $9 and kept a Buy ...

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in ...

– Expanded deal brings Omeros $115 million upfront payment and opportunity for additional $55 million in sales-based milestones – SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today ...

The MarketWatch News Department was not involved in the creation of this content. Interest expense during the first quarter of 2025 was $3.7 million compared to $8.2 million during the prior year ...

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) (“Omeros” or the “Company”) today announced that it has entered into exchange agreements (the “Exchange Agreements”) with a limited number of ...

Shares of Omeros Corporation (NASDAQ: OMER), a rising star in the biotech industry, are losing altitude after the company reported first-quarter earnings today. The stock was down 16% earlier this ...

The ARTEMIS-IGAN trial did not reach statistical significance on the primary endpoint of reduction in proteinuria from baseline compared to placebo Proteinuria reduction in the placebo group was ...

For online access to the live webcast of the conference call, go to Omeros’ website at https://investor.omeros.com/upcoming-events. To access the live conference ...